Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Current use of noninvasive prenatal testing in Europe, Australia and the USA: A graphical presentation

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Gadsbøll, K, Petersen, OB, Gatinois, V, Strange, H, Jacobsson, B, Wapner, R, Robert Vermeesch, J, Vogel, I & NIPT-map study group 2020, 'Current use of noninvasive prenatal testing in Europe, Australia and the USA: A graphical presentation' Acta Obstetricia et Gynecologica Scandinavica, vol. 99, no. 6, pp. 722-730. https://doi.org/10.1111/aogs.13841

APA

CBE

MLA

Vancouver

Author

Gadsbøll, Kasper ; Petersen, Olav Bjørn ; Gatinois, Vincent ; Strange, Heather ; Jacobsson, Bo ; Wapner, Ronald ; Robert Vermeesch, Joris ; Vogel, Ida ; NIPT-map study group. / Current use of noninvasive prenatal testing in Europe, Australia and the USA : A graphical presentation. In: Acta Obstetricia et Gynecologica Scandinavica. 2020 ; Vol. 99, No. 6. pp. 722-730.

Bibtex

@article{6fe79acbadd64741a9c9d80cbca7af04,
title = "Current use of noninvasive prenatal testing in Europe, Australia and the USA: A graphical presentation",
abstract = "Introduction: Noninvasive prenatal testing (NIPT) using cell-free fetal DNA has increasingly been adopted as a screening tool for fetal aneuploidies. Several studies have discussed benefits and limitations of NIPT compared with both ultrasound and invasive procedures, but in spite of some shortcomings NIPT has become extensively used within the last 5 years. This study aims to describe the current use of NIPT in Europe, Australia and the USA. Material and methods: We conducted a survey to describe the current use of NIPT. Colleagues filled in a simple email-based questionnaire on NIPT in their own country, providing information on (a) access to NIPT, (b) NIPT’s chromosomal coverage, (c) financial coverage of NIPT for the patient and (d) the proportion of women using NIPT in pregnancy. Some data are best clinical estimates, due to a lack of national data. Results: In Europe, 14 countries have adopted NIPT into a national policy/program. Two countries (Belgium and the Netherlands) offer NIPT for all pregnant women, whereas most other European countries have implemented NIPT as an offer for higher risk women after first trimester screening. In Australia, either combined first trimester screening (cFTS) or NIPT is used as a primary prenatal screening test. In the USA, there are no national consensus policies on the use of NIPT; however, NIPT is widely implemented. In most European countries offering NIPT, the proportion of women using NIPT is well below 25{\%}. In the Netherlands, Austria, Italy, Spain and most Australian and American States, 25{\%}-50{\%} of women have NIPT performed and in Belgium testing is above 75{\%}. In most countries, NIPT reports on trisomy 13, 18 and 21, and often also on sex chromosome aneuploidies. Only in Belgium, the Netherlands, Lithuania, Greece, Cyprus and Italy is NIPT offered predominantly as a genome-wide test (including some microdeletions or a whole genome coverage). Conclusions: Noninvasive prenatal testing has been widely adopted throughout Europe, Australia and the USA, but only a few countries/states have a national policy on the use of NIPT. The variation in NIPT utilization is considerable.",
keywords = "cell-free fetal DNA, combined first trimester screening, noninvasive prenatal testing, prenatal genetic screening",
author = "Kasper Gadsb{\o}ll and Petersen, {Olav Bj{\o}rn} and Vincent Gatinois and Heather Strange and Bo Jacobsson and Ronald Wapner and {Robert Vermeesch}, Joris and Ida Vogel and {NIPT-map study group}",
note = "{\circledC} 2020 Nordic Federation of Societies of Obstetrics and Gynecology.",
year = "2020",
month = "6",
doi = "10.1111/aogs.13841",
language = "English",
volume = "99",
pages = "722--730",
journal = "Acta Obstetricia et Gynecologica Scandinavica",
issn = "0001-6349",
publisher = "Informa Healthcare",
number = "6",

}

RIS

TY - JOUR

T1 - Current use of noninvasive prenatal testing in Europe, Australia and the USA

T2 - A graphical presentation

AU - Gadsbøll, Kasper

AU - Petersen, Olav Bjørn

AU - Gatinois, Vincent

AU - Strange, Heather

AU - Jacobsson, Bo

AU - Wapner, Ronald

AU - Robert Vermeesch, Joris

AU - Vogel, Ida

AU - NIPT-map study group

N1 - © 2020 Nordic Federation of Societies of Obstetrics and Gynecology.

PY - 2020/6

Y1 - 2020/6

N2 - Introduction: Noninvasive prenatal testing (NIPT) using cell-free fetal DNA has increasingly been adopted as a screening tool for fetal aneuploidies. Several studies have discussed benefits and limitations of NIPT compared with both ultrasound and invasive procedures, but in spite of some shortcomings NIPT has become extensively used within the last 5 years. This study aims to describe the current use of NIPT in Europe, Australia and the USA. Material and methods: We conducted a survey to describe the current use of NIPT. Colleagues filled in a simple email-based questionnaire on NIPT in their own country, providing information on (a) access to NIPT, (b) NIPT’s chromosomal coverage, (c) financial coverage of NIPT for the patient and (d) the proportion of women using NIPT in pregnancy. Some data are best clinical estimates, due to a lack of national data. Results: In Europe, 14 countries have adopted NIPT into a national policy/program. Two countries (Belgium and the Netherlands) offer NIPT for all pregnant women, whereas most other European countries have implemented NIPT as an offer for higher risk women after first trimester screening. In Australia, either combined first trimester screening (cFTS) or NIPT is used as a primary prenatal screening test. In the USA, there are no national consensus policies on the use of NIPT; however, NIPT is widely implemented. In most European countries offering NIPT, the proportion of women using NIPT is well below 25%. In the Netherlands, Austria, Italy, Spain and most Australian and American States, 25%-50% of women have NIPT performed and in Belgium testing is above 75%. In most countries, NIPT reports on trisomy 13, 18 and 21, and often also on sex chromosome aneuploidies. Only in Belgium, the Netherlands, Lithuania, Greece, Cyprus and Italy is NIPT offered predominantly as a genome-wide test (including some microdeletions or a whole genome coverage). Conclusions: Noninvasive prenatal testing has been widely adopted throughout Europe, Australia and the USA, but only a few countries/states have a national policy on the use of NIPT. The variation in NIPT utilization is considerable.

AB - Introduction: Noninvasive prenatal testing (NIPT) using cell-free fetal DNA has increasingly been adopted as a screening tool for fetal aneuploidies. Several studies have discussed benefits and limitations of NIPT compared with both ultrasound and invasive procedures, but in spite of some shortcomings NIPT has become extensively used within the last 5 years. This study aims to describe the current use of NIPT in Europe, Australia and the USA. Material and methods: We conducted a survey to describe the current use of NIPT. Colleagues filled in a simple email-based questionnaire on NIPT in their own country, providing information on (a) access to NIPT, (b) NIPT’s chromosomal coverage, (c) financial coverage of NIPT for the patient and (d) the proportion of women using NIPT in pregnancy. Some data are best clinical estimates, due to a lack of national data. Results: In Europe, 14 countries have adopted NIPT into a national policy/program. Two countries (Belgium and the Netherlands) offer NIPT for all pregnant women, whereas most other European countries have implemented NIPT as an offer for higher risk women after first trimester screening. In Australia, either combined first trimester screening (cFTS) or NIPT is used as a primary prenatal screening test. In the USA, there are no national consensus policies on the use of NIPT; however, NIPT is widely implemented. In most European countries offering NIPT, the proportion of women using NIPT is well below 25%. In the Netherlands, Austria, Italy, Spain and most Australian and American States, 25%-50% of women have NIPT performed and in Belgium testing is above 75%. In most countries, NIPT reports on trisomy 13, 18 and 21, and often also on sex chromosome aneuploidies. Only in Belgium, the Netherlands, Lithuania, Greece, Cyprus and Italy is NIPT offered predominantly as a genome-wide test (including some microdeletions or a whole genome coverage). Conclusions: Noninvasive prenatal testing has been widely adopted throughout Europe, Australia and the USA, but only a few countries/states have a national policy on the use of NIPT. The variation in NIPT utilization is considerable.

KW - cell-free fetal DNA

KW - combined first trimester screening

KW - noninvasive prenatal testing

KW - prenatal genetic screening

U2 - 10.1111/aogs.13841

DO - 10.1111/aogs.13841

M3 - Journal article

VL - 99

SP - 722

EP - 730

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 6

ER -

ID: 59614321